Literature DB >> 15378210

Polarization of immunity induced by direct injection of naked sequence-stabilized mRNA vaccines.

J-P Carralot1, J Probst, I Hoerr, B Scheel, R Teufel, G Jung, H-G Rammensee, S Pascolo.   

Abstract

In the context of developing a safe genetic vaccination strategy we tested and studied globin-stabilized mRNA-based vaccination in mice. This vaccination strategy has the advantages of genetic vaccination (easy production, adaptability to any disease and inexpensive storage when lyophilized), but not the drawbacks of DNA vaccination (long-term uncontrolled expression of a transgene, possibility of integration into the host genome and possible induction of anti-DNA antibodies). We report here that injection of naked beta-globin untranslated region (UTR)-stabilized mRNA coding for beta-galactosidase is followed by detectable translation in vivo. In addition, we show that such a vaccination strategy primes a T helper 2 (Th2) type of response which can be enhanced and shifted to a Th1-type immune response by application of recombinant granulocyte/macrophage colony-stimulating factor 1 day after mRNA injection. Our data demonstrate that the administration of globin UTR-stabilized mRNA is a versatile vaccination strategy that can be manipulated to fit the requirement of antiviral, antibacterial or antitumor immunity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15378210      PMCID: PMC7079797          DOI: 10.1007/s00018-004-4255-0

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  37 in total

1.  Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients.

Authors:  Susanne M Rittig; Maik Haentschel; Katrin J Weimer; Annkristin Heine; Martin R Muller; Wolfram Brugger; Marius S Horger; Olga Maksimovic; Arnulf Stenzl; Ingmar Hoerr; Hans-Georg Rammensee; Tobias A W Holderried; Lothar Kanz; Steve Pascolo; Peter Brossart
Journal:  Mol Ther       Date:  2010-12-28       Impact factor: 11.454

Review 2.  Developing mRNA-vaccine technologies.

Authors:  Thomas Schlake; Andreas Thess; Mariola Fotin-Mleczek; Karl-Josef Kallen
Journal:  RNA Biol       Date:  2012-10-12       Impact factor: 4.652

3.  Lipid Nanoparticle Assisted mRNA Delivery for Potent Cancer Immunotherapy.

Authors:  Matthias A Oberli; Andreas M Reichmuth; J Robert Dorkin; Michael J Mitchell; Owen S Fenton; Ana Jaklenec; Daniel G Anderson; Robert Langer; Daniel Blankschtein
Journal:  Nano Lett       Date:  2016-12-05       Impact factor: 11.189

Review 4.  mRNA-based therapeutics--developing a new class of drugs.

Authors:  Ugur Sahin; Katalin Karikó; Özlem Türeci
Journal:  Nat Rev Drug Discov       Date:  2014-09-19       Impact factor: 84.694

Review 5.  Immunotherapy in gastric cancer.

Authors:  Satoko Matsueda; David Y Graham
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

Review 6.  mRNA vaccine CV9103 and CV9104 for the treatment of prostate cancer.

Authors:  Steffen Rausch; Christian Schwentner; Arnulf Stenzl; Jens Bedke
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 7.  RNA vaccines in cancer treatment.

Authors:  Anita Bringmann; Stefanie Andrea Erika Held; Annkristin Heine; Peter Brossart
Journal:  J Biomed Biotechnol       Date:  2010-06-01

8.  Intranasal vaccination with messenger RNA as a new approach in gene therapy: use against tuberculosis.

Authors:  Julio C C Lorenzi; Ana P F Trombone; Carolina D Rocha; Luciana P Almeida; Ricardo L Lousada; Thiago Malardo; Isabela C Fontoura; Renata A M Rossetti; Ana F Gembre; Aristóbolo M Silva; Celio L Silva; Arlete A M Coelho-Castelo
Journal:  BMC Biotechnol       Date:  2010-10-20       Impact factor: 2.563

9.  Long-term storage of DNA-free RNA for use in vaccine studies.

Authors:  Kathryn L Jones; Debbie Drane; Eric J Gowans
Journal:  Biotechniques       Date:  2007-11       Impact factor: 1.993

10.  mRNA Vaccine with Antigen-Specific Checkpoint Blockade Induces an Enhanced Immune Response against Established Melanoma.

Authors:  Yuhua Wang; Lu Zhang; Zhenghong Xu; Lei Miao; Leaf Huang
Journal:  Mol Ther       Date:  2017-11-21       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.